Ligand specificity, privileged substructures and protein druggability from fragment-based screening

被引:43
作者
Barelier, Sarah [1 ]
Krimm, Isabelle [1 ]
机构
[1] Univ Lyon 1, CNRS, Analyt Sci Lab, UMR 5180, F-69622 Villeurbanne, France
关键词
MAXIMAL AFFINITY; INHIBITOR; DESIGN; BCL-X(L); BIOLOGY; POTENT; VIEW;
D O I
10.1016/j.cbpa.2011.02.020
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fragment-based screening has now become an established method for the generation of lead molecules against therapeutic targets. Fragment molecules are simple, low molecular-weight compounds with few chemical functionalities. These characteristics lead to high hit rates for fragment screening as compared to the more classical High-Throughput Screening of drug-like molecules and raise the question of the specificity of fragment molecules. This review analyzes recent outcomes of fragment screenings published in the literature, showing that the specificity of the fragments can be related to their structures and physico-chemical properties. We also discuss both the concept of privileged fragment scaffolds and the role of fragment-based screening in predicting protein druggability, highlighted by recent publications in the field.
引用
收藏
页码:469 / 474
页数:6
相关论文
共 44 条
[1]   Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors [J].
Akritopoulou-Zanze, Irini ;
Hajduk, Philip J. .
DRUG DISCOVERY TODAY, 2009, 14 (5-6) :291-297
[2]   Deconstructing fragment-based inhibitor discovery [J].
Babaoglu, Kerim ;
Shoichet, Brian K. .
NATURE CHEMICAL BIOLOGY, 2006, 2 (12) :720-723
[3]   Ligand Specificity in Fragment-Based Drug Design [J].
Barelier, Sarah ;
Pons, Julien ;
Gehring, Kalle ;
Lancelin, Jean-Marc ;
Krimm, Isabelle .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5256-5266
[4]   Discovery of Fragment Molecules That Bind the Human Peroxiredoxin 5 Active Site [J].
Barelier, Sarah ;
Linard, Dominique ;
Pons, Julien ;
Clippe, Andre ;
Knoops, Bernard ;
Lancelin, Jean-Marc ;
Krimm, Isabelle .
PLOS ONE, 2010, 5 (03)
[5]   Fragment-Based Deconstruction of Bcl-xL Inhibitors [J].
Barelier, Sarah ;
Pons, Julien ;
Marcillat, Olivier ;
Lancelin, Jean-Marc ;
Krimm, Isabelle .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (06) :2577-2588
[6]   A Medicinal Chemist's Guide to Molecular Interactions [J].
Bissantz, Caterina ;
Kuhn, Bernd ;
Stahl, Martin .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5061-5084
[7]   Rediscovering the sweet spot in drug discovery [J].
Brown, D ;
Superti-Furga, G .
DRUG DISCOVERY TODAY, 2003, 8 (23) :1067-1077
[8]   VASP: A Volumetric Analysis of Surface Properties Yields Insights into Protein-Ligand Binding Specificity [J].
Chen, Brian Y. ;
Honig, Barry .
PLOS COMPUTATIONAL BIOLOGY, 2010, 6 (08)
[9]   Lessons for fragment library design: analysis of output from multiple screening campaigns [J].
Chen, I-Jen ;
Hubbard, Roderick E. .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2009, 23 (08) :603-620
[10]   Molecular docking and ligand specificity in fragment-based inhibitor discovery [J].
Chen, Yu ;
Shoichet, Brian K. .
NATURE CHEMICAL BIOLOGY, 2009, 5 (05) :358-364